All In Biotech

Drug Trial Radar · NCT02682238

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Local Tolerability of Topically Applied BBI-4000 (Sofpironium Bromide) 15% Gel in Subjects With Palmar Hyperhidrosis

Last checked: Nov 20, 2026Latest source record: May 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Mar 8, 2016

Primary completion

Jul 14, 2016

Study completion Oct 4, 2016

Sponsor

Lead sponsor
Botanix PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.

Conditions

  • Hyperhidrosis

Interventions

  • BBI-4000, 15%Drug

  • Vehicle gelOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment Emergent Adverse Events by SeverityTime frame: Baseline visit-Day 42 End of Participation

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • TCR Medical Corporation

    San Diego, California

  • International Dermatology Research, Inc.

    Miami, Florida

  • Shideler Clinical Research Center

    Carmel, Indiana

  • Saint Louis University Dermatology

    St Louis, Missouri

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.